T. Rowe Price Associates
FBIO icon

T. Rowe Price Associates’s Fortress Biotech FBIO Stock Holding History

T. Rowe Price Associates’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-78,816
Closed -$8.3M – 2495
2013
Q3 		$8.3M Buy
78,816
+1,580
+2% +$194K ﹤0.01% 1313
2013
Q2 		$9.96M Buy
+77,236
New +$11.4M ﹤0.01% 1252

Other funds holding FBIO

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
MOACM
Mutual of America Capital Management New York $8.8B AUM 29.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

T. Rowe Price Associates's FBIO Position: Q4 2013 in Review

T. Rowe Price Associates sold out of Fortress Biotech (FBIO) in Q4 2013, closing a stake of 78,816 shares — an estimated $8.3M sold.

T. Rowe Price Associates first reported a position in FBIO in Q2 2013 and held it in 2 quarters. The position peaked at $9.96M in Q2 2013. 60 funds tracked by Wall St. Rank hold FBIO as of Q4 2013.

  • T. Rowe Price Associates reported no remaining Fortress Biotech position as of Q4 2013 after selling out during the quarter.
  • T. Rowe Price Associates sold 78,816 Fortress Biotech shares in Q4 2013, an estimated $8.3M.
  • T. Rowe Price Associates first reported a position in Fortress Biotech in Q2 2013 and held it in 2 quarters.
  • T. Rowe Price Associates's Fortress Biotech position peaked at $9.96M in Q2 2013.
  • 60 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2013.

Based on T. Rowe Price Associates's 13F filing for Q4 2013, filed 14 Feb 2014.